Feb 14 (Reuters) - CSL Ltd CSL.AX
* FDA accepts CSL Behring's biologics license application supplement for using privigen to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare neurological condition Source text for Eikon: ID:nPn9tlJ5ta Further company coverage: CSL.AX